CE-IVD marking of Novodiag® CarbaR+, the 3rd molecular test on the automated system Novodiag®, for detection of the main Carbapenemase-Producing…
The article presents the results of the multicentric prospective study carried out in the framework of the Hepystool Hospital Clinical…
Mobidiag has entered into a joint venture agreement with Autobio Diagnostics, one of the leading clinical diagnostics companies in China,…
Mobidiag will host a symposium at the 38th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI), in Paris this month. Mobidiag will…
In the scope of the World Antibiotic Awareness Week 2018, Bpifrance (French Public Investment Bank) has highlighted the French key…
Mobidiag announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company…
The article features the successful evaluation by the Leicester Royal Infirmary of Amplidiag® Easy, the automated solution for routine diagnostic…
Mobidiag will hold a new symposium at the 38ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse in Paris, France. Register now! Mobidiag…
The article focuses on Novodiag® solution, the automated molecular diagnostic system allowing rapid and reliable results directly from patient sample.…
Released in 2016 for the detection of most relevant carbapenemase groups as well as vancomycin resistance markers from pure culture…